The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis.
comorbidities
drug-drug interactions
fertile age
multiple sclerosis
polypharmacy
women
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
03
2020
accepted:
01
10
2020
entrez:
11
1
2021
pubmed:
12
1
2021
medline:
12
1
2021
Statut:
epublish
Résumé
Multiple sclerosis (MS) is the most common neuroimmunological disease of the central nervous system in young adults. Despite recommended contraception, unplanned pregnancies can occur in women of childbearing age with MS. MS- and comorbidities-related multimedication in these patients represents a potential risk. We aimed to raise awareness regarding the frequency of polypharmacy and drug-drug interactions (DDIs) in female MS patients of childbearing age. Sociodemographic, clinical and pharmaceutical data were collected through patient records, clinical investigations and structured patient interviews of 131 women with MS. The clinical decision support software MediQ was used to identify potential DDIs. A medication and DDI profile of the study population was created by statistical analysis of the recorded data. Of the 131 female MS patients, 41.2% were affected by polypharmacy (concurrent use of ⩾5 drugs). Polypharmacy was associated with higher age, higher degree of disability, chronic progressive MS disease course and comorbidities. With an average intake of 4.2 drugs per patient, a total of 1033 potential DDIs were identified. Clinically relevant DDIs were significantly more frequent in patients with polypharmacy than in patients without polypharmacy (31.5% For the first time, a comprehensive range of potential DDIs in women of childbearing age with MS is presented. Polypharmacy is associated with the occurrence of clinically relevant DDIs. This shows the need for effective and regular screening for such interactions in order to prevent avoidable adverse effects.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Multiple sclerosis (MS) is the most common neuroimmunological disease of the central nervous system in young adults. Despite recommended contraception, unplanned pregnancies can occur in women of childbearing age with MS. MS- and comorbidities-related multimedication in these patients represents a potential risk. We aimed to raise awareness regarding the frequency of polypharmacy and drug-drug interactions (DDIs) in female MS patients of childbearing age.
METHODS
METHODS
Sociodemographic, clinical and pharmaceutical data were collected through patient records, clinical investigations and structured patient interviews of 131 women with MS. The clinical decision support software MediQ was used to identify potential DDIs. A medication and DDI profile of the study population was created by statistical analysis of the recorded data.
RESULTS
RESULTS
Of the 131 female MS patients, 41.2% were affected by polypharmacy (concurrent use of ⩾5 drugs). Polypharmacy was associated with higher age, higher degree of disability, chronic progressive MS disease course and comorbidities. With an average intake of 4.2 drugs per patient, a total of 1033 potential DDIs were identified. Clinically relevant DDIs were significantly more frequent in patients with polypharmacy than in patients without polypharmacy (31.5%
CONCLUSION
CONCLUSIONS
For the first time, a comprehensive range of potential DDIs in women of childbearing age with MS is presented. Polypharmacy is associated with the occurrence of clinically relevant DDIs. This shows the need for effective and regular screening for such interactions in order to prevent avoidable adverse effects.
Identifiants
pubmed: 33425014
doi: 10.1177/1756286420969501
pii: 10.1177_1756286420969501
pmc: PMC7758868
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756286420969501Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: NF received travel funds for research meetings from Novartis. MH received speaking fees and travel funds from Bayer HealthCare, Biogen, Merck Serono, Novartis and Teva. SEL declares no competing interests. PM declares no competing interests. MCH declares no competing interests. UKZ received research support and lecture fees or travel funds from Alexion, Almirall, Bayer HealthCare, Biogen, Merck Serono, Novartis, Roche, Sanofi and Teva.
Références
Ther Adv Neurol Disord. 2020 Mar 9;13:1756286420910310
pubmed: 32201504
Lancet. 2018 Apr 21;391(10130):1622-1636
pubmed: 29576504
Mult Scler. 2015 Mar;21(3):282-93
pubmed: 25533299
BMC Med. 2018 Nov 12;16(1):205
pubmed: 30415641
Int J Clin Pharm. 2017 Oct;39(5):1128-1139
pubmed: 28823018
J Clin Med Res. 2018 Nov;10(11):806-814
pubmed: 30344815
Acta Neurol Scand. 2014 Mar;129(3):154-62
pubmed: 24256407
J Am Coll Cardiol. 2018 May 15;71(19):2149-2161
pubmed: 29747836
Pain. 2020 Apr;161(4):787-796
pubmed: 32197038
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
Expert Opin Drug Saf. 2020 Feb;19(2):139-145
pubmed: 31965869
Mult Scler Relat Disord. 2015 May;4(3):273-80
pubmed: 26008945
Eur J Neurol. 2019 Jan;26(1):27-40
pubmed: 30300457
Expert Opin Pharmacother. 2018 Apr;19(5):483-498
pubmed: 29528247
Mult Scler. 2019 Oct;25(12):1641-1652
pubmed: 30230952
Neurology. 2017 Nov 28;89(22):2222-2229
pubmed: 29093064
World J Urol. 2001 Nov;19(5):319-23
pubmed: 11760780
Med Clin North Am. 2015 May;99(3):521-34
pubmed: 25841598
Pharmacoepidemiol Drug Saf. 2014 May;23(5):489-97
pubmed: 24616171
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurology. 2016 Apr 12;86(15):1446-1453
pubmed: 26865523
Eur J Health Econ. 2017 Dec;18(9):1069-1078
pubmed: 27913940
Ann Pharmacother. 2013 Mar;47(3):324-32
pubmed: 23482734
J Rehabil Med. 2017 Mar 6;49(3):193-203
pubmed: 28233010
Eur J Clin Pharmacol. 2015 Nov;71(11):1389-96
pubmed: 26300207
Expert Rev Clin Pharmacol. 2014 Jul;7(4):533-44
pubmed: 24745854
Stud Fam Plann. 2014 Jun;45(2):151-69
pubmed: 24931073
Hamostaseologie. 2019 Feb;39(1):42-48
pubmed: 30669160
CNS Neurosci Ther. 2018 Sep;24(9):784-789
pubmed: 29635832
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Drugs. 2011 Oct 1;71(14):1893-915
pubmed: 21942978
Continuum (Minneap Minn). 2019 Jun;25(3):773-792
pubmed: 31162316
Mult Scler. 2020 Mar 12;:1352458520910497
pubmed: 32162580
Pract Neurol. 2018 Feb;18(1):35-42
pubmed: 28947637
Med J Aust. 2019 Sep;211(5):230-236
pubmed: 30919466
JAMA Neurol. 2018 Aug 1;75(8):1013-1021
pubmed: 29710293
Mult Scler. 2010 Sep;16(9):1031-43
pubmed: 20551086
Clin Invest Med. 2019 Mar 23;42(1):E5-E12
pubmed: 30904030
Hum Reprod. 2018 May 1;33(5):777-783
pubmed: 29659848
Fortschr Neurol Psychiatr. 2019 May;87(5):320-332
pubmed: 31125990
Autoimmun Rev. 2017 Sep;16(9):925-936
pubmed: 28698092
Clin Pharmacol Ther. 2011 Oct;90(4):588-96
pubmed: 21866099
BMC Geriatr. 2017 Oct 10;17(1):230
pubmed: 29017448
Curr Treat Options Neurol. 2018 Mar 17;20(4):8
pubmed: 29549521
J Neurol. 2007 May;254 Suppl 2:II112-5
pubmed: 17503118
Clin Endocrinol (Oxf). 2015 Jan;82(1):136-41
pubmed: 25040647
Mult Scler. 2017 May;23(6):757-764
pubmed: 28338393
Nervenarzt. 2018 Mar;89(3):319-326
pubmed: 28741067
Drug Saf. 2013 Apr;36(4):247-58
pubmed: 23494998
CNS Drugs. 2018 Feb;32(2):117-133
pubmed: 29417493
Nat Rev Neurol. 2017 Jun;13(6):375-382
pubmed: 28303911
Mult Scler J Exp Transl Clin. 2019 Dec 12;5(4):2055217319891744
pubmed: 31853368
Autoimmun Rev. 2012 Jan;11(3):167-73
pubmed: 21619943
Int Rev Psychiatry. 2017 Oct;29(5):463-472
pubmed: 28681616
Autoimmun Rev. 2016 Mar;15(3):210-20
pubmed: 26589194
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
J Neurol. 2009 Nov;256(11):1932-5
pubmed: 19629565
PLoS One. 2018 Jul 31;13(7):e0198004
pubmed: 30063697